After a turbulent year in the gene therapy field, the 3rd Gene Therapy Potency Assay Summit returns at a time when drug developers are increasingly recognizing that it is business-critical to have a robust potency assay to support clinical and commercial progress.

For potency assay experts, there is no other meeting offering in-depth technical discussions with a genuine expert community who are uniting to discuss essential sticking points like phase-appropriate assay development, methodology progress, reducing lot-to-lot variability, and aligning to changing regulatory guidelines.

Engage with analytical leads to discuss shared pain points, new technologies enabling improved predictability, and hear perspectives from those who have been through IND-enabling studies and all the way to commercialization of their gene therapy products.

URLs:

Tickets: https://go.evvnt.com/2886105-2?pid=91 

Brochure: https://go.evvnt.com/2886105-3?pid=91 

Prices:

Conference Only - Drug Developer Pricing: USD 2999.00,

Conference Only - Academic Pricing: USD 2599.00,

Conference Only - Service Provider Pricing: USD 3699.00

Speakers: Anoosha Forghani, Bioanalytics Genomic Medicine Scientist, Sanofi, George Opoku-Kusi, Principal Scientist - Analytical, Cell and Gene Therapy, Regeneron Pharmaceuticals, Gillian Payne, Former Vice President - Analytical Development, Carbon Biosciences, Hunghao Chu, Associate Director, Benitec Ltd, Hyosuk Cho, Scientist II, Bioassay Analytical Development, Sangamo Therapeutics, Jie Li, Director, Vertex Pharmaceuticals, Jing Li, Associate Director, Alexion Pharmaceuticals, Kan Zhu, Associate Director, CSL, Kelly Fitzpatrick, Senior Director, Analytical Development, Beam Therapeutics Inc., Melody Dai, Vice President, Head of Regulatory Affairs and CMC, Novasenta, Qingwei Deng, Head, Analytical Development, Gene Therapy, UCB, Rebecca Lyth, Senior Scientist, Analytical Development, AviadoBio, Scott Jeffers, Chief Technology Officer, GenSight Biologics, Yickhong Lam, Scientist, Sanofi, Yonghong Yang, Director, Prime Medicine